65,723 Shares in Pfizer Inc. $PFE Bought by Janney Capital Management LLC

Janney Capital Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 65,723 shares of the biopharmaceutical company’s stock, valued at approximately $1,675,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Brighton Jones LLC lifted its position in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in Pfizer by 12.9% in the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 25,035 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 2,858 shares during the period. Goldstone Financial Group LLC boosted its position in Pfizer by 53.8% during the second quarter. Goldstone Financial Group LLC now owns 25,241 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 8,832 shares during the last quarter. Finally, Czech National Bank grew its holdings in Pfizer by 6.8% during the 2nd quarter. Czech National Bank now owns 1,389,705 shares of the biopharmaceutical company’s stock worth $33,686,000 after acquiring an additional 88,131 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: New oncology data showed a Pfizer cancer combination produced stronger tumor shrinkage versus standard treatment in advanced colorectal cancer — supportive for commercial/label expansion prospects in a high‑value oncology indication. Pfizer cancer combo shows strong tumor shrinkage in colorectal cancer trial
• Positive Sentiment: Pfizer advanced a lung‑cancer combo into a global Phase 2/3 program and launched a head‑to‑head colorectal cancer Phase 3 for PF‑08634404 — progress that de‑risks late‑stage oncology pipeline timing and future revenue potential. Pfizer advances new lung cancer combo in global Phase 2/3 trial
• Positive Sentiment: Positive data on Pfizer’s Braftovi regimen were reported, reinforcing the company’s targeted‑therapy franchise and near‑term oncology catalysts. Positive new data on Pfizer’s Braftovi regimen
• Positive Sentiment: CEO Albert Bourla signaled ambition to build an obesity consumer market comparable to Viagra’s consumer expansion; that, plus the $10B Metsera acquisition, positions Pfizer to capture a potentially large, recurring market if regulatory/launch execution succeeds. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
• Positive Sentiment: BMO reiterated a Buy and $30 price target, highlighting oncology, obesity pipeline upside and post‑LOE recovery prospects as key upside drivers. Pfizer: Underappreciated Growth Story
• Neutral Sentiment: Zacks’ preview of Q4 suggests oncology revenue will see steady growth from Seagen ADCs and key brands but be partially offset by pricing and competitive pressures — a mixed operational outlook ahead of earnings. Inside Pfizer’s Oncology Performance Ahead of Q4 Results
• Neutral Sentiment: Broker actions are mixed: UBS flagged the Metsera deal favorably but kept a Neutral stance ($25 PT), and the street average rating is around Hold — indicating uncertainty on near‑term revenue trajectory. UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE Pfizer Receives Average “Hold” Rating
• Neutral Sentiment: Pfizer’s JPMorgan presentation material was published (slides/transcript) — useful for detail on strategy and pipeline but not an immediate stock mover absent new guidance. Pfizer Presents at J.P. Morgan Healthcare Conference
• Negative Sentiment: Pfizer stopped a mid‑stage lupus skin trial, removing a smaller autoimmune opportunity and signaling a pipeline setback that may reduce near‑term upside from non‑oncology indications. Pfizer Ends Mid-Stage Lupus Skin Trial
• Negative Sentiment: Analysts and commentators continue to flag legacy risks — a looming patent cliff, rising debt and earnings pressure post‑LOE — which cap valuation upside until clearer revenue recovery paths materialize. Pfizer’s Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Citigroup assumed coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price on the stock. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $27.88.

Pfizer Stock Performance

Shares of PFE stock opened at $25.12 on Wednesday. The firm has a market capitalization of $142.83 billion, a PE ratio of 14.60 and a beta of 0.47. The firm has a fifty day simple moving average of $25.29 and a two-hundred day simple moving average of $24.97. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is currently 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.